Horizon Therapeutics Pub L Stock Price, News & Analysis

Horizon Therapeutics (Nasdaq: HZNP) announced new MRI data from the Phase 3 clinical trial of UPLIZNA, highlighting its efficacy in reducing asymptomatic optic nerve lesions in patients with NMOSD. The results, presented at the NANOS meeting (March 11-16, 2023), indicate that UPLIZNA not only decreased the risk of NMOSD-associated attacks but also demonstrated a reduction in subclinical optic nerve enhancements over time. UPLIZNA is the only B-cell depleting monotherapy approved for this condition, reinforcing its clinical significance. These findings enhance understanding of the treatment's impact on disease progression.

Horizon Therapeutics announced real-world analysis results of TEPEZZA for Thyroid Eye Disease (TED) patients with dysthyroid optic neuropathy (DON) at the NANOS Annual Meeting (March 11-16) in Orlando. Among 24 patients, most previously unresponsive to treatments, TEPEZZA demonstrated significant visual acuity improvements (mean lines of improvement: 3.7) and reduced proptosis (mean reduction: 4.4 mm). Adverse events included fatigue and hearing issues, consistent with clinical trials. The study reinforces TEPEZZA’s role in addressing severe TED cases, emphasizing its importance for patients at high risk of vision loss.

Horizon Therapeutics announced that as of February 23, 2023, its ordinary share capital consists of 228,832,390 Ordinary Shares and 40,000 deferred ordinary shares, with a nominal value of $0.0001 each. The company also holds 384,366 treasury shares. Additionally, there are 4,758,722 outstanding options and 1,810,200 restricted stock units that can convert into Ordinary Shares. Both the Ordinary Shares and the deferred shares are traded on Nasdaq under the ticker symbol HZNP.

Information adheres to the Irish Takeover Rules, and the directors accept responsibility for its accuracy.

Horizon Therapeutics reported Q4 2022 net sales of $942 million, down 7% from Q4 2021. For the full year, net sales reached a record $3.63 billion, marking a 12% year-over-year increase. The company achieved GAAP net income of $120.4 million for Q4, and $521.5 million for the year. Adjusted EBITDA for the year was a record $1.37 billion. Key product performances included TEPEZZA with $493.5 million in Q4 net sales, and KRYSTEXXA with a 27% growth. Horizon announced a definitive agreement to be acquired by Amgen, expected to close in the first half of 2023.

Horizon Therapeutics (NASDAQ: HZNP) has opened applications for its 2023 #RAREis Global Advocate Grant, which offers 50 advocacy groups a one-time grant of $5,000 each. The application period runs until March 31, 2023. This initiative aims to enhance support for the rare disease community, addressing challenges faced by approximately 400 million individuals globally. In 2022, 30 grants were awarded to organizations representing 29 unique rare diseases. A livestream event is scheduled for February 28 to discuss advocacy issues within this community and showcase the impact of the grants.

Horizon Therapeutics plc (NASDAQ: HZNP) has announced that its shareholders approved a cash acquisition offer from Pillartree Limited, a subsidiary of Amgen Inc., at both the scheme meeting and extraordinary general meeting. The resolution to approve the scheme was passed with 99.89% of shares voted in favor, with a total of 173,076,982 shares representing 75.78% of total shareholding. The EGM also showed strong support for the resolutions, including an amendment to the articles of association. The transaction is pending approval from the Irish High Court but is expected to finalize in the first half of 2023, following regulatory clearance in several European countries.

Horizon Therapeutics plc (Nasdaq: HZNP) announced new data from post-hoc analyses of the N-MOmentum clinical trial regarding UPLIZNA, a treatment for neuromyelitis optica spectrum disorder (NMOSD). These analyses, presented at the ACTRIMS Forum, indicate that UPLIZNA does not increase COVID-19 susceptibility nor affect antibody levels from childhood vaccinations. Among 182 patients, only 0.024 COVID infections per patient year were reported. Additionally, after 3.5 years, antibody titers related to vaccines remained stable. This supports UPLIZNA's long-term efficacy and favorable safety profile in AQP4-IgG+ NMOSD patients.

Horizon Therapeutics plc (NASDAQ: HZNP) will release its fourth-quarter and full-year 2022 financial results on March 1, 2023, before U.S. markets open. This announcement follows the company's recent acquisition agreement with Amgen. Due to this acquisition, Horizon will not hold a conference call to discuss the financial results. Investors can access the earnings release on the Investor Relations page of Horizon's website. Horizon focuses on developing therapies for rare and autoimmune diseases, emphasizing their commitment to delivering meaningful treatments to patients in need.

Horizon Therapeutics plc (NASDAQ: HZNP) has received a cash offer from Pillartree Limited, a company wholly owned by Amgen Inc.. This Proposed Transaction aims to acquire the entire ordinary share capital of Horizon through a scheme of arrangement under the Irish Companies Act of 2014. Both companies announced the terms of the offer on December 12, 2022, with a joint letter sent to stakeholders detailing the proposal.

Shareholders are urged to review the Proxy Statement filed with the SEC on January 23, 2023 for comprehensive details about the vote.